Recent Updates
Recently added Catalysts
TMDX Positive Sentiment

TransMedics to Report Second Quarter 2023 Financial Results on August 3, 2023 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

Key Takeaway: TransMedics Group, Inc. (Nasdaq: TMDX) announced plans to release its second quarter 2023 financial results on August 3, 2023. The management team will host a conference call at 4:30 p.m. ET to discuss the financial outcomes. TransMedics specializes in portable extracorporeal warm perfusion technology for organ transplantation and aims to improve organ quality and viability assessments for patients with end-stage organ failure.
Price reaction · baseline $92.11 (2023-07-19 close) · hit after-hours · clean, no other TMDX news in the window
day 0 close · peak
-1.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • TransMedics is transforming organ transplant therapy, addressing a critical need.
  • They are the world's leader in organ perfusion and assessment technology.
  • Upcoming financial results indicate transparency and communication with investors.

Full Press Release Details

ANDOVER, Mass. , July 20, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2023 after market close on Thursday, August 3, 2023 . The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT .
Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domestic callers or (412) 317-5415 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/ .
About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Frequently Asked Questions

When will TransMedics report Q2 2023 financial results?

TransMedics will release Q2 2023 financial results after market close on August 3, 2023.

How can investors join the TransMedics conference call?

Investors can join the call by dialing (866) 807-9684 for domestic or (412) 317-5415 for international.

Where can I find the TransMedics conference call webcast?

A live and archived webcast will be available in the 'Investors' section of their website.

What is TransMedics known for?

TransMedics is known for portable extracorporeal warm perfusion and organ assessment technology.

What is the main focus of TransMedics?

TransMedics focuses on improving organ transplantation for patients with end-stage organ failure.

Last updated: Jul 20, 2023